Journal of Clinical Virology
Volume 47, Issue 1 , Pages 8-12 , January 2010

Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients

  • Maria Grazia Milia

      Affiliations

    • Microbiology and Virology Laboratory, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Torino, Italy
    • ,
  • Tizano Allice

      Affiliations

    • Microbiology and Virology Laboratory, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Torino, Italy
    • ,
  • Gabriella Gregori

      Affiliations

    • Microbiology and Virology Laboratory, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Torino, Italy
    • ,
  • Stefano Mussino

      Affiliations

    • Microbiology and Virology Laboratory, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Torino, Italy
    • ,
  • Giancarlo Orofino

      Affiliations

    • Department of Infectious Diseases, Ospedale Amedeo di Savoia, Torino, Italy
    • ,
  • Stefano Bonora

      Affiliations

    • Department of Infectious Diseases, Ospedale Amedeo di Savoia, Torino, Italy
    • ,
  • Valeria Ghisetti

      Affiliations

    • Microbiology and Virology Laboratory, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Torino, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 011 4393 967; fax: +39 011 4393 820.

Received 23 August 2009 ,Revised 29 September 2009 ,Accepted 12 October 2009.

References 

  1. Hirsch SM. Antiretroviral drug resistance testing in adult HIV-1 Infection: 2008, vol. 47. Recommendations of an International AIDS Society, USA Panel CID; 2008;pp. 266–285
  2. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. November 3, 2008, http://aidsinfo.nih.gov.
  3. Mackie N. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods. 2004;119(2):73–78
  4. Peuchant O, Thiébaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, Morlat P, et al. ANRS CO3 Aquitaine Cohort. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008;31:1417–142322(12)
  5. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 2008;29(57):e158
  6. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis. 2009;15(482):239–247
  7. Toni TA, Asahchop EL, Moisi D, Ntemgwa M, Oliveira M, Masquelier B, et al. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother. 2009;53(April (4)):1670–1672
  8. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15(April (2)):247–277
  9. Roquebert B, Malet I, Wirden M, Tubiana R, Valantin MA, Simon A, et al. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS. 2006;20(January (2)):287–289
  10. Metzner KJ, Rauch P, Walter H, Boesecke C, Zöllner B, Jessen H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS. 2005;19(November (16)):1819–1825
  11. Verhofstede C, Fransen K, Marissens D, Verhelst R, van der Groen G, Lauwers S, et al. Isolation of HIV-1 RNA from plasma: evaluation of eight different extraction methods. J Virol Methods. 1996;60(2):155–159
  12. Daar ES. Incorporating novel virologic tests into clinical practice. Top HIV Med. 2007;15(August–September (4)):126–129
  13. Ruelle J, Jnaoui K, Lefèvre I, Lamarti N, Goubau P. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol. 2009;44(4):297–301
  14. Sloma CR, Germer JJ, Gerads TM, Mandrekar JN, Mitchell PS, Yao JD. Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol. 2009;47(4):889–895
  15. Scott LE, Noble LD, Moloi J, Erasmus L, Venter WD, Stevens W. An evaluation of the Abbott m2000 RealTime HIV-1 assay for HIV viral load monitoring in South Africa compared to existing technologies: Roche COBAS Ampliprep/COBAS Amplicor; Roche COBAS Ampliprep/COBAS TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1. J Clin Microbiol. 2009;47(7):2209–2217
  16. Schutten M, Fries E, Burghoorn-Maas C, Niesters HG. Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. J Clin Virol. 2007;40(2):99–104
  17. Scott L, Carmona S, Stevens W. The performance of the new Roche COBAS Ampliprep/COBAS TaqMan HIV-1 version 2.0 assay. J Clin Microbiol; in press
  18. Gueudin M, Plantier JC, Lemée V, Schmitt MP, Chartier L, Bourlet T, et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr. 2007;15(44(5)):500–505
  19. Jongerius JM, Sjerps M, Cuijpers HT, van Drimmelen HA, van der Poel CL, Reesink HW, et al. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. Transfusion. 2002;42(6):792–797
  20. Germer JJ, Vandenameele JN, Mitchell PS, Harmsen WS, Yao JD. Automated sample preparation for the TRUGENE HIV-1 genotyping kit using the MagNA pure LC instrument. Diagn Microbiol Infect Dis. 2004;49(May (1)):59–61
  21. McClernon DR, Ramsey E, Clair MS. Magnetic silica extraction for low-viremia human immunodeficiency virus type 1 genotyping. J Clin Microbiol. 2007;45(2):572–574
  22. Eshleman S, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, et al. Sensitivity and specificity of the ViroSeq HIV-1 genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol. 2005;43:813–817
  23. Maes B, Schrooten Y, Snoeck J, Derdelinckx I, Van Ranst M, Vandamme AM, et al. Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods. 2004;119(1):45–49
  24. Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn. 2006;8(September (4)):430–432
  25. Stanford resistance database. http://hivdb.stanford.edu/.
  26. Johnson V. Update of the drug resistance mutations in HIV-1: December 2008. International AIDS Society–USA Top HIV Med. 2008;16(5):138–145
  27. Shafer R, Schapiro J. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008;10:67–84
  28. de Mendoza C. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. AIDS Rev. 2009;11(January–March (1)):39–51

PII: S1386-6532(09)00502-2

doi: 10.1016/j.jcv.2009.10.012

Journal of Clinical Virology
Volume 47, Issue 1 , Pages 8-12 , January 2010

Article Tools

* Image Usage & Resolution